The use of tegaserod in critically ill patients with impaired gastric motility

Clinical Pharmacology and Therapeutics

Volumn 77, Issue 6, 2005, Pages 583-586

  Banh, Hoan Linh ^a   MacLean, Charles ^b   Topp, Trevor ^b   Hall, Richard ^b  

^a QUEEN ELIZABETH II HEALTH SCIENCES CENTRE   (Canada)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMLODIPINE; CEFAZOLIN; DALTEPARIN; DEXAMETHASONE; ENALAPRIL; FENTANYL; HEPARIN; IPRATROPIUM BROMIDE; MEROPENEM; METOCLOPRAMIDE; NIMODIPINE; RANITIDINE; SALBUTAMOL; TEGASEROD;

ABDOMINAL AORTA ANEURYSM; ADULT; AGED; ARTICLE; ARTIFICIAL VENTILATION; CASE REPORT; CRITICAL ILLNESS; DIARRHEA; DRUG SAFETY; ENTERIC FEEDING; HUMAN; INTENSIVE CARE UNIT; MALE; PRIORITY JOURNAL; QT PROLONGATION; SPINAL CORD COMPRESSION; SPINE FRACTURE; STOMACH EMPTYING; STOMACH MOTILITY; STOMACH PARESIS; SUBARACHNOID HEMORRHAGE; VOMITING;

AGED; CRITICAL ILLNESS; GASTROINTESTINAL AGENTS; GASTROINTESTINAL MOTILITY; GASTROPARESIS; HUMANS; INDOLES; MALE; MIDDLE AGED; SEROTONIN AGONISTS;

EID: 20444449818     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clpt.2005.02.002     Document Type: Article

References (38)

1. G.P. Zologa Early enteral nutrition support improves outcome hypothesis or fact? Crit Care Med 27 1999 259 261
2. S.J. Taylor, S.B. Fettes, C. Jewkes, R.J. Nelson Prospective, randomized, controlled trial to determine the effect of early enhanced enteral nutrition on clinical outcome in mechanically ventilated patients suffering head injury Crit Care Med 27 1999 2525 2531
3. L. Kompan, B. Kremzar, E. Gadzijev, M. Prosek Effects of early enteral nutrition on intestinal permeability and the development of multiple organ failure after multiple injury Int Care Med 25 1999 157 161
4. S.A. McClave, H.L. Snider, C.C. Lowen, A.J. McLaughlin, L.M. Greene, R.J. McCombs Use of residual volume as a marker for enteral feeding intolerance prospective blinded comparison with physical examination and radiographic findings JPEN J Parenter Enteral Nutr 16 1992 99 105
5. H.D. Spapen, L. Duinslaeger, M. Diltoer, R. Gillet, A. Bossuyt, L.P. Huyghens Gastric emptying in critically ill patients is accelerated by adding cisapride to a standard enteral feeding protocol results of a prospective, randomized controlled trials Crit Care Med 23 1995 481 485
6. D.K. Heyland, G. Tougas, D.J. Cook, G.H. Guyatt Cisapride improves gastric emptying in mechanically ventilated, critically ill patients a randomized, double-blind trial Am J Respir Crit Care Med 154 1996 1678 1683
7. D.R. Goldhill, C.C. Toner, M.M. Tarling, K. Baxter, P.S. Withington, R. Whelpton Double-blind, randomized study of the effect of cisapride on gastric emptying in critically ill patients Crit Care Med 25 1997 447 451
8. C.A. Jooste, J. Mustoe, G. Collee Metoclopramide improves gastric motility in critically patients Intensive Care Med 25 1999 464 468
9. R.M. Calcroft, G. Jont, C.D. Gomersall, V. Hung Gastric emptying in critically ill patients a randomized, blinded, prospective comparison of metoclopramide with placebo Intensive Care Med 25 1999 13339 13340
10. A. Dive, C. Miesse, L. Galanti, J. Jamart, P. Evrard, M. Gonzalez Effect of erythromycin on gastric motility in mechanically ventilated critically ill patients Crit Care Med 23 1995 1356 1362
11. C.F. Pollera, F. Cognetli, M. Nardi, D. Mozza Sudden death after acute dystonic reaction to high-dose metoclopramide Lancet 2 1984 460 461
12. G. Bentsen, A. Stubbaug Cardiac arrest after intravenous metoclopramide-a case of five repeated injections of metoclopramide causing five episodes of cardiac arrest Acta Anaesthesiol Scand 46 2002 908 910
13. E. Ellidokuz, D. Kaya The effect of metoclopramide on QT dynamicity double-blind, placebo-controlled, cross-over study in healthy male volunteers Aliment Pharmacol Ther 18 2003 151 155
14. E. Bruera, R. Villamayor, E. Roca, M. Barugel, J. Tronge, R. Chacon QT interval prolongation and ventricular fibrillation with IV domperidone Cancer Treat Rep 70 1986 545 546
15. B. Drolet, G. Rousseau, P. Daleau, R. Cardinal, J. Turgeon Domperidone should not be considered a no-risk alternative to cisapride in the treatment of gastrointestinal motility disorders Circulation 102 2000 1883 1885
16. + channel by gastrointestinal prokinetic agent cisapride Am J Physiol 273 1997 H2534 H2538
17. D. Rampe, M.L. Roy, A. Dennis, A.M. Brown A mechanism for the proarrhythmic effects of cisapride (Propulsid) High affinity blockade of the human cardiac potassium channel HERG FEBS Lett 471 1997 28 32
18. B. Drolet, M. Khalifa, P. Daleau, B.A. Hamelin, J. Turgeon Block of the rapid component agent cisapride underlies drug-related lengthening of the QT interval Circulation 97 1998 204 210
19. K.C. Oberg, J.L. Bauman QT interval prolongation and torsades de pointes due to erythromycin lactobionate Pharmacotherapy 15 1995 687 692
20. 4 receptor Eur J Pharmacol 241 1993 125 128
21. 4 receptors Am J Physiol 277 1999 G515 G520
22. J.R. Grider, A.E. Foxx-Orenstein, J.G. Jin 5-Hydroxytrytamine-4 receptor agonists initiate the peristaltic reflex in human, rat, and guinea pig intestine Gastroenterology 115 1998 370 380
23. 3 receptors J Pharmacol Exp Ther 288 1999 93 97
24. 4 receptor agonist, in a model of slow colonic transit Clin Pharmacol Ther 62 1997 546 555
25. 4 receptor agonist, accelerates gastric emptying and gastrointestinal transit in healthy male subjects Aliment Pharmacol Ther 15 2001 1745 1751
26. M.M. Tarling, C.C. Toner, P.S. Withington, M.K. Baxter, R. Whelpton, D.R. Goldhill A model of gastric emptying using paracetamol absorption in intensive care patients Intensive Care Med 23 1997 256 260
27. 4 receptor Med Res Rev 13 1993 633 662
28. M. Costa, S.J. Brookes The enteric nervous system Am J Gastroenterol 89 1994 S129 S137
29. M. Gershon Roles played by 5-hydroxytryptamine in the physiology of the bowel Aliment Pharmacol Ther 13 Suppl 1999 15 30
30. 4 receptor, in gastrointestinal motility J Gastroenterol 35 2000 575 582
31. M.B. Hansen Neurohumoral control of gastrointestinal motility Physiol Res 52 2003 1 30
32. 4 receptor partial agonist with promotile activity Clin Pharmacokinet 41 2002 1021 1042
33. A. Nguyen, M. Camilleri, L.J. Kost, A. Metzger, M.G. Sarr, R.B. Hanson SDZ HTF 919 stimulates canine colonic motility and transit in vivo J Pharmacol Exp Ther 280 1997 1270 1276
34. A.E. Vickers, M. Zollinger, R. Dannecker, R. Tynes, F. Heitz, V. Fischer In vitro metabolism of tegaserod in human liver and intestine assessment of drug interactions Drug Metab Dispos 29 2001 1269 1276
35. 4 receptor partial agonist is devoid of significant electrographic side effects Am J Gastroenterol 97 2002 2321 2327
36. M.D. Drici, S.N. Ebert, W.X. Wang, I. Rodriguez, X.K. Liu, B.H. Whitfield Comparison of tegaserod (HTF 919) and its main human metabolite with cisapride and erythromycin on cardiac repolarization in the isolated rabbit heart J Cardiovascular Pharmacol 34 1999 82 88
37. G. Tougas, W.J. Snape Jr, M.H. Otten, D.L. Earnest, K.E. Langaker, R.E. Pruitt Long-term safety of tegaserod in patients with constipation-predominant irritable bowel syndrome Aliment Pharmacol Ther 16 2002 1701 1708
38. M. Camilleri Tegaserod Aliment Pharmacol Ther 15 2001 277 289